Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT00271687 Completed - Prostatic Neoplasms Clinical Trials

A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer

Start date: February 2006
Phase: Phase 2
Study type: Interventional

This study aims to provide preliminary data on the feasibility and outcomes of a 12 week exercise program on the quality of life of men with hormone refractory prostate cancer receiving docetaxel-based chemotherapy.

NCT ID: NCT00270049 Completed - Cancer Clinical Trials

Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia

Start date: November 1990
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of treatment with epoetin alfa versus placebo on the percentage of red blood cells in anemic patients with chronic lymphocytic (white blood cell) leukemia and its effect on the patients' quality-of-life. Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.

NCT ID: NCT00269997 Completed - Neoplasms Clinical Trials

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of epoetin alfa versus placebo in the treatment of persistent anemia caused by advanced cancer and aggressive cisplatin chemotherapy. Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.

NCT ID: NCT00268840 Completed - Clinical trials for Pancreatic Neoplasms

The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer

Start date: August 2001
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy of combination therapy with gemcitabine and docetaxelin in patients with locally advanced or metastatic pancreatic or biliary adenocarcinoma.

NCT ID: NCT00267553 Terminated - Breast Neoplasms Clinical Trials

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

Start date: November 2005
Phase: Phase 3
Study type: Interventional

Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibitor (AI) atamestane combined with the FDA-approved anti-estrogen toremifene (Fareston®), to the single agent FDA-approved aromatase inhibitor letrozole (Femara®) for the treatment of advanced breast cancer. The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of atamestane, plus toremifene (Fareston®), is more effective than letrozole (Femara®) in delaying the growth of breast cancer.

NCT ID: NCT00266617 Completed - Neoplasms Clinical Trials

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of epoetin alfa in the treatment of persistent anemia caused by advanced cancer and aggressive adriamycin-chemotherapy. Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.

NCT ID: NCT00266279 Completed - Head or Neck Cancer Clinical Trials

Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies

Start date: April 2005
Phase: Phase 2
Study type: Interventional

This phase II study will test the response rate of combined oxaliplatin and capecitabine treatment when administered at a given dose and schedule, in patients with Head and Neck cancer for which there is no curative treatment.

NCT ID: NCT00266084 Completed - Clinical trials for Uterine Cervical Cancer

Clinical Trial for the Use of a Novel Cell Collector Device to Retrieve Cells From the Uterine Cervix

Start date: August 1999
Phase: Phase 1/Phase 2
Study type: Observational

This study tested the safety and performance of a new cell collector device and compared the results to those obtained with the current existing device that are being used routinely

NCT ID: NCT00265057 Completed - Neoplasms Clinical Trials

Study of ADH-1 Given Intravenously to Patients With Solid Tumors

Start date: June 2005
Phase: Phase 1/Phase 2
Study type: Interventional

N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with incurable, solid tumors with a protein biomarker called N-cadherin. This study will identify the amount of ADH-1 that subjects can tolerate.

NCT ID: NCT00264472 Suspended - Neoplasms Clinical Trials

A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors

Start date: January 2006
Phase: Phase 1
Study type: Interventional

5 fluorouracil (5 FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This study will test the safety and effects of oral ADH300004 14 hours prior to oral 5 FU in subjects with refractory solid tumors.